封面
市場調查報告書
商品編碼
2150680

過敏免疫療法市場報告:趨勢、預測和競爭分析(至2035年)

Allergy Immunotherapy Market Report: Trends, Forecast and Competitive Analysis to 2035

出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

過敏免疫療法市場

受過敏性鼻炎和過敏性氣喘市場機會的推動,全球過敏免疫療法市場前景光明。預計全球過敏免疫療法市場規模將從2027年的43億美元成長至2035年的76億美元,2027年至2035年的複合年成長率(CAGR)為7.1%。推動該市場成長的關鍵因素包括過敏性疾病盛行率的上升、人們對過敏治療意識的增強以及個人化醫療的日益普及。

  • 根據 Lucintel 的預測,鑑於有證據表明皮下免疫療法在治療嚴重過敏症方面有效,預計在預測期內,皮下免疫療法的成長率將更高。
  • 從跡象來看,接觸環境過敏原的增加表明,在預測期內,過敏性鼻炎領域有望出現更高的成長。
  • 從區域來看,亞太地區預計將在預測期內呈現最高的成長率,因為隨著空氣污染加劇,過敏症的診斷數量也在增加。

過敏免疫療法市場的新趨勢

預計在2025年至2027年間,過敏免疫療法將轉向早期檢測和居家治療。在此期間,治療重點也將放在控制疾病進展上。 Lucintel認為,過敏和免疫療法市場的變化將增加對過敏治療的需求。這主要得益於保險覆蓋範圍的擴大、新型生技藥品和其他產品的研發以及其他趨勢。

  • 個人化治療:對個別風險的日益關注將影響過敏處方。 FDA批准新的口服製劑也預計將促進口服免疫療法的推廣。 2025年,相關指南制定完成,旨在將風險獲益評估方法引入花生和堅果過敏的治療中。預計過敏治療的定價和市場定位也將呈現類似趨勢。
  • 居家治療:近年來,隨著科技的進步,在家治療過敏性疾病已成為可能。這包括使用連網型設備監測治療依從性以及利用遠端醫療進行遠端監測。
  • 食物過敏治療:近期核准的緩解食物過敏的產品為開發其他減輕過敏症狀的產品鋪平了道路。生物製藥產業近期專注於緩解食物過敏的趨勢預計將持續。
  • 數位化患者支援:症狀日記、自動提醒和遠端指導可以幫助醫療服務提供者和製藥公司支持患者管理症狀,並堅持完成治療。數位科技將有助於產生關於治療依從性的真實世界數據,並有助於消除意外的治療中斷。因此,數位化方法可能會加速健保覆蓋治療的恢復,並且至少在2030年之前都將保持其有效性。
  • 永續製造:製藥公司需履行報告義務,將醫療保健的永續性納入其中。因此,供應商正在維修其設施和供應鏈,以提高資源利用效率。改變生產流程需要大量資金。企業期望供應商投資於提高資源利用效率。醫療保健提供者採購流程向永續製造的轉變將會加速。

最終,市場成功與否取決於能否研發出有效的食物過敏治療方法,並使其能夠在醫療體系之外惠及病患。其他優勢,例如治療的連續性,也將有助於市場成功。數位科技的整合將提升治療安全性。有利於製造商進入食物過敏市場的法規將有助於確保患者獲得安全有效的治療。

過敏免疫療法市場的最新趨勢

2025年至2027年間,隨著舌下含片的普及、生物製藥類過敏性鼻炎療法的出現以及市場相關人員對這些產品長期經濟影響的評估,過敏免疫療法市場預計將持續成長。根據Lucintel公司預測,過敏性鼻炎盛行率的上升預計將推動市場需求。然而,仍有許多挑戰,包括病患接受度、治療順從性以及合格醫護人員的短缺等。

  • 法規環境:美國食品藥物管理局(FDA) 和歐洲監管機構正在加速開發標準化的舌下免疫療法產品。 FDA 於 2024 年 6 月批准 Odactra 用於 5 至 65 歲患者,這項批准樹立了監管先例,將為其他舌下片劑的市場化鋪平道路。產品供應的改善可能使基層醫療醫生能夠在診所和診療環境中使用這些產品。
  • 生產環境:標準化過敏原萃取物的供應預計將會增加。 2025年,Staller宣布將在三年內投資1億美元,以擴大其生產設施的產能。供應量的增加將使企業能夠拓展其產品銷售的區域市場。
  • 策略聯盟:抗過敏藥物研發公司正與專注於藥物依從性和診斷的公司合作,建構端到端解決方案。抗過敏藥物尤其受益於持續的病患監測,以評估治療的連續性。上述兩家公司之間的聯盟預計到2025年價值將達到約2,000萬美元。
  • 新的研究領域:一些公司正在探索過敏原免疫療法與生物製藥的聯合應用。如果這些正在進行的臨床試驗取得積極成果,則有望擴大該療法的適用患者範圍,並提高每位患者的平均收入。
  • 持續療效的證據:到2025年,部分提供歐盟醫保覆蓋的抗過敏藥目標產品的生產商必須證明,患者在治療的第二年和第三年仍能持續受益。能夠提供患者用藥依從性及三年以上持續治療證據的產品符合上述要求。

抗過敏藥物生產商必須投入大量資金擴大其藥物的健保覆蓋範圍,以增加目標患者群。然而,他們的成功取決於能否證明其產品符合「持續緩解疾病」的要求。否則,醫療保險公司和專業人士將對其產品實施價格管制和醫保覆蓋範圍限制。

目錄

第1章執行摘要

第2章 市場概覽

  • 背景與分類
  • 供應鏈

第3章 市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章:全球過敏免疫療法市場:按類型分類

  • 吸引力分析:按類型
  • 皮下免疫療法
  • 舌下免疫療法

第5章 全球過敏免疫療法市場:依應用領域分類

  • 吸引力分析:依目的
  • 過敏性鼻炎
  • 過敏性氣喘
  • 其他

第6章 區域分析

第7章:北美過敏免疫療法市場

  • 北美過敏免疫療法市場:按類型分類
  • 北美過敏免疫療法市場:按應用領域分類
  • 美國過敏免疫療法市場
  • 加拿大過敏免疫療法市場
  • 墨西哥的過敏免疫療法市場

第8章:歐洲過敏免疫療法市場

  • 歐洲過敏免疫療法市場:按類型分類
  • 歐洲過敏免疫療法市場:按應用領域分類
  • 德國過敏免疫療法市場
  • 法國過敏免疫療法市場
  • 義大利過敏免疫療法市場
  • 西班牙過敏免疫療法市場
  • 英國過敏免疫療法市場

第9章:亞太地區過敏免疫療法市場

  • 亞太地區過敏免疫療法市場:按類型分類
  • 亞太地區過敏免疫療法市場:按應用領域分類
  • 中國過敏免疫療法市場
  • 印度過敏免疫療法市場
  • 日本過敏免疫療法市場
  • 韓國過敏免疫療法市場
  • 印尼過敏免疫療法市場

第10章:世界其他地區的過敏免疫療法市場

  • 其他地區的過敏免疫療法市場:按類型分類
  • 其他地區的過敏免疫療法市場:按應用領域分類
  • 中東過敏免疫療法市場
  • 南美洲過敏免疫療法市場
  • 非洲過敏免疫療法市場

第11章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析
  • 市佔率分析

第12章 機會與策略分析

  • 價值鏈分析
  • 成長機會分析
  • 新趨勢:全球過敏免疫療法市場
  • 戰略分析

第13章:價值鏈中關鍵企業的公司概況

  • 競爭分析概述
  • ALK-Abello
  • Stallergenes Greer
  • Merck
  • Allergy Therapeutics
  • HAL
  • Holister Stier
  • Leti

第14章附錄

Allergy Immunotherapy Market

The future of the global allergy immunotherapy market looks promising with opportunities in the allergic rhinitis and allergic asthma markets. The global allergy immunotherapy market is expected to reach an estimated $7.6 billion by 2035 from $4.3 billion in 2027 with a CAGR of 7.1% from 2027 to 2035. The major drivers for this market are the increasing prevalence of allergic conditions, the rising awareness of allergy treatments, and the growing adoption of personalized therapies.

  • Lucintel forecasts that, within the type category, subcutaneous immunotherapy is expected to witness higher growth over the forecast period due to evidence that shows that subcutaneous immunotherapy is effective in treating severe allergies.
  • Within the application category, allergic rhinitis is expected to witness higher growth over the forecast period due to heightened exposure to environmental allergens.
  • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to pollution is on the rise and so are the number of medical diagnoses for allergies.

Emerging Trends in Allergy Immunotherapy Market

Between 2025 and 2027, Allergy immunotherapy will shift toward early detection and home treatment. During this period, treatment will also focus on modifying the condition to slow its progression. Lucintel believes that changes in the allergy and immunotherapy market will increase the demand for allergy therapy. This will be a result of improvements in payer coverage, development of novel biologics and other products, and other trends.

  • Personalized Treatment: Increasing focus on individual risk will influence the prescription of allergy treatment. Additional oral products from the FDA will also influence the expansion of oral immunotherapy. In 2025, guidelines also introduced a risk-benefit approach to the consideration of peanut and tree nut allergy treatment. Similar trends are anticipated in the pricing and market positioning of allergy treatment.
  • Home Treatment: Recent advances have also enabled the modification of treatment for allergic conditions to be conducted at home. These include the use of connected devices to monitor treatment adherence and telehealth to conduct remote monitoring.
  • Food Allergy Treatment: The recent approval of a product to modify food allergy has also created an avenue for the development of other products to modify allergy conditions. The recent focus of the biopharmaceutical industry on modifying food allergy conditions is expected to continue.
  • Digital Patient Support: Symptom diaries, automated reminders, and remote coaching enable providers and manufacturers to support patients in managing symptoms, and adhering to and persisting on their treatment. Digital techniques will facilitate generation of real-world data on treatment adherence and will help address unintentional treatment discontinuation. Therefore, digital approaches will facilitate restoration of reimbursed treatment and will be useful at least until 2030.
  • Sustainable Manufacturing: Pharmaceutical companies have reporting requirements that integrate health care sustainability. As a result, suppliers are modifying their facilities and supply chain to improve their resource efficiency. Manufacturing changes require considerable capital. Companies expect their suppliers will invest in improving resource efficiency. Changes in health care provider companies' procurement processes to incorporate sustainable manufacturing will accelerate.

Ultimately, success in the market will be determined by the ability to develop effective treatment options for food allergy that can be administered to patients outside the healthcare system. Other advantages such as treatment persistence will contribute to the market success. Integrating digital technologies will enhance treatment safety. Regulations that facilitate manufacturers' entry into the food allergy market will help ensure that patients have access to safe, and effective treatment options.

Recent Developments in the Allergy Immunotherapy Market

Between 2025 and 2027, we expect the allergy immunotherapy market to expand as sublingual tablets become more widely available, biologics-based allergic rhinitis products arrive, and market players assess the long-term economic impact of these products. According to Lucintel, the demand will be driven by the increasing prevalence of allergic rhinitis. However, there are obstacles such as the level of acceptance and willingness of the patient to adhere to the treatment, as well as the availability of specialized personnel.

  • Regulatory Environment: The U.S. Food and Drug Administration (FDA) and the European agencies are facilitating the development of standardized sublingual immunotherapy products. The FDA's approval of Odactra for use by patients 5 through 65 years of old (June 2024) sets a regulatory precedent that will allow other sublingual tablet products to be marketed. A shift in product availability may allow primary care physicians to administer the products in a office or clinic setting.
  • Manufacturing Environment: The supply of standardized allergen extracts is anticipated to increase. In 2025, Staller genes Greer announced a three-year, $100 million investment to increase the capacity of its manufacturing facilities. The increased supply may allow companies to expand the geographic markets in which they can sell their products.
  • Strategic Partnerships: Allergy drug developers are partnering with companies that specialize in adherence and diagnosis to create end-to-end solutions. Allergy drugs, in particular, benefit from continuous patient monitoring to assess treatment persistence. The 2025 collaboration between the two aforementioned companies was worth around $20 million.
  • New Avenues of Research: Some companies explore the combination of allergen immunotherapy with biologics. Positive results of these ongoing clinical trials are likely to broaden the scope of the patient population for which the treatment is indicated and increase average revenue per patient.
  • Evidence of Sustained Benefit: In 2025, some Allergy drug companies providing products reimbursed by the European Union, had to show that patients continued to benefit from the product in the 2nd and 3rd year of treatment. Products supported by evidence of patient adherence and persistence over a 3-year period met the above requirement.

Allergy drug companies have to invest substantially to increase the addressable patient population by broadening the indication for which their drugs are reimbursed. However, success will depend on a company's ability to demonstrate that their product meets the requirement of durable disease modification. Failure to do so will result in price control and reimbursement restriction by health care benefit payers and specialists.

Strategic Growth Opportunities in the Allergy Immunotherapy Market

An increase in allergies from 2024-2026 is expected to drive demand for allergy treatments. During this timeframe, reducing the cost of medications is also expected to put increasing demand on the supply of allergy treatments. Digital consultations will allow treatments to be given in the home. According to Lucintel, the allergy immunotherapy market will see growth by 2026, primarily due to investment in the biologics market and improvements in access to care.

  • Paediatric Populations: In June 2025 the FDA approved ODACTRA for use in patients 5-17 years of age. Newer and more effective interventions for treating allergies may gain coverage and reimbursement if they lead to improved outcomes for patients.
  • Home Therapies: SLIT has the potential to be a highly profitable allergy treatment. In 2024, ALK reported that their allergy treatment sales reached 5.1 billion DKK. In the coming years, allergists will be able to treat more patients and help control their symptoms.
  • Biologic Combination Therapies: In February 2025 the FDA approved biologics to treat asthma. There are a number of patients that do not benefit from the use of current allergy treatments. Combination therapies that include the use of biologics may treat patients that do not benefit from the use of allergy treatments.
  • Making Allergy Treatment More Accessible: Local manufacturing and variance in pricing make allergy treatment more accessible in other regions. May 2025 was a landmark date as the population of India reached 1.4 billion. Each year provides additional opportunities for training more physicians and expanding the population that can be treated.
  • Adherence Services: Telehealth services and electronic reminders can improve treatment adherence. The use of electronic devices to manage health increased in 2025. Electronic devices can also be used to improve treatment adherence. Improved adherence can also facilitate the reimbursement of treatment.

In the next five years, regional manufacturing and the adoption of allergy treatment in the pediatric population will increase. The treatment of allergies will become more integrated into various healthcare pathways. Biologic combinations will also increase. The focus on adherence will also continue. Manufacturing and distributing allergy treatment will remain more lucrative in developed countries.

Allergy Immunotherapy Market Drivers and Challenges

The immunotherapy market is expected to grow due to advancements in technology and changes in the economics, regulations and attitudes toward allergic diseases and health care. The focus on improving symptoms has now expanded to include other means of modifying allergic diseases. The availability of more convenient, tolerable and effective ways to treat allergic diseases has increased the demand for allergy immunotherapy. Patents covering allergy immunotherapy have expired, creating a more competitive marketplace. Restrictive reimbursement policies and the need for lengthy treatment regimens continue to limit the market potential. The outcome of future clinical trials will determine the market potential of allergy immunotherapy. The most promising opportunity for competitive advantage will be captured by those companies that are able to commercialize the innovative allergy immunotherapies in a timely manner.

The factors responsible for driving this market include:

  • Rising Cases of Allergies: The number of people suffering from allergic conditions is increasing due to exposure to various environmental factors. According to the World Health Organization (WHO), hundreds of millions of people suffer from allergic conditions and related conditions. In 2025, Public Health England documented a significant increase in the awareness of allergic conditions. The longer duration of pollen shedding and exposure of various environmental conditions facilitate the diagnosis of allergic conditions. Consequently, there will be an increase in the demand for therapies to manage allergic conditions in the coming years. Additionally, the awareness of the public on available treatments for allergic conditions will increase, especially on the availability of immunotherapies to manage and prevent allergic conditions.
  • Availability of New Technologies: In the coming years, the allergy immunotherapy market will be enhanced with the development of new technologies. The collaboration of biotechnology and other related disciplines will improve diagnosis of various allergic conditions and develop immunotherapies. Digital adherence technology will improve the confidence of healthcare providers in remote management of allergic conditions and other chronic conditions. Hospitals will be able to provide personalized management for allergic conditions based on the recommendations of remote healthcare providers.
  • Regulatory and Clinical Support: Standardized allergen products are gaining regulatory and clinical acceptance. Immunotherapy products are available in major markets. Long-term immune responses and indication expansion are evaluated. Regulatory pathways allow for post-market research and increase product acceptability. Product credibility will increase if evidence of long-lasting benefits is generated. In the next 3-5 years, expected changes to the regulatory and reimbursement landscape, coupled with revised clinical practice guidelines, will allow for the integration of Allergy Immunotherapy for select patient populations.
  • Demand for Long-Term Disease Modification: Allergic patients prefer long-term therapies to control their symptoms rather than relying on the use of rapidly acting emergency and/or symptom-modifying therapies. Allergy Immunotherapy is receiving increased attention. Many expect long-lasting and durable benefits from therapy. The use of Allergy Immunotherapy is increasing, and both the sublingual and injectable routes of administration are gaining preference. In the next 3-5 years, therapies offering long-term benefits and durability will be welcomed by the patient population, particularly if they decrease symptom frequency and severity and allow for improvement in quality of life.
  • Manufacturing and Distribution: Allergen extraction and quality control processes have improved, as have cold-chain and specialty pharmacy logistics. Digital prescription and dispense technologies allow for the traceability of prescription medications. Manufacturers have adopted these processes in order to ensure consistent and reliable allergy treatment. Visibility to the allergy treatment supply chain has been the focus of several Federal initiatives. Continuity of treatment is directly correlated to supply chain interruptions. Further manufacturing improvements should facilitate an increase in the number of standardized allergy treatment options. Manufacturing enhancements and process improvements should lower the cost of these treatments and improve access. During the next 5 years, the focus of allergy treatment manufacturers should be to expand their product offerings and extend the geographic reach of their offerings beyond the allergist's office.

The challenges facing this market include:

  • High Treatment Cost and Lack of Reimbursement: The cost of treatment over the long term places an enormous burden on the patient and the allergist. Allergy treatment requires multiple office visits over several years. Treatment plans are often not initiated due to lack of insurance coverage. Even when treatment plans are initiated, there may not be adequate coverage for the entire treatment plan. Several barriers exist to the timely, and completion, of treatment plans. It is expected that in the next 5 years treatment plans will not be initiated, or completed, due to high out of pocket costs, even if lower long term costs (i.e. less asthmatic episodes, less allergy flare-ups, fewer medication usage, improved quality of life, improved workplace attendance, etc.) are achieved.
  • Safety Concerns and Adherence Challenges: The potential for severe reactions after each injection, the need for many clinic visits, and the inability to stop treatment even after symptoms improve, all contribute to a lack of adherence to treatment among patients. Various procedures to reduce risks and increase safety have added to the time and cost required for treatment. As seen with sublingual alternatives, there are ways to reduce some of the barriers associated with treatment; however, these methods still require daily use. Improved adherence will likely occur only with the use of more innovative and less complex methods, and through better risk management and educational strategies.
  • Inadequate Diagnosis and Allergist Capacity: There are untreated patients with allergic conditions, and trained nurses and allergists are not equally located throughout a given area. Long wait times for testing and the inability of some clinics to provide treatment for a large number of patients lead to an inadequate allocation of resources and restriction of treatment to only a small number of patients. This is likely to continue in the next several years, particularly in less-developed nations. While several strategies have been developed to better diagnose and test patients, including the use of telemedicine, the ongoing need to comply with various laws and the protection of patient safety will likely slow the distribution of treatment to a greater degree.

The growing prevalence of allergies, as well as higher awareness of allergies amongst the population, is expected to benefit the allergy immunotherapy market. More effective technology will allow companies to develop and commercialize products that will positively influence the allergy immunotherapy market. There are several barriers to market growth, including product costs, safety concerns, and the lack of specialty care providers. Barriers will likely allow market leaders to develop products that improve consumer compliance and increase the range of products distributed. Maintaining a balance between developing and commercializing products that meet consumer needs and embrace improving technology will allow companies to maintain market leadership. The focus of companies will likely be on innovating products while keeping the needs of consumers at the centre.

List of Allergy Immunotherapy Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies allergy immunotherapy market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the allergy immunotherapy market companies profiled in this report include-

  • ALK-Abello
  • Stallergenes Greer
  • Merck
  • Allergy Therapeutics
  • HAL
  • HollisterStier
  • LETI

Allergy Immunotherapy Market by Segment

The study includes a forecast for the global allergy immunotherapy market by type, application, and region.

Allergy Immunotherapy Market by Type [Value ($B) from 2019 to 2035]:

  • Subcutaneous Immunotherapy
  • Sublingual Immunotherapy

Allergy Immunotherapy Market by Application [Value ($B) from 2019 to 2035]:

  • Allergic Rhinitis
  • Allergic Asthma
  • Others

Allergy Immunotherapy Market by Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Allergy Immunotherapy Market

The allergy immunotherapy market is growing because of more allowing manufacturers to produce sublingual tablets in more locations and because of a greater acceptance of sublingual therapies. About 2025-2027, companies plan to increase the number of products they can make and increase the labels on their products. The effects of these plans are causing increased market competition, both in established markets and in new markets, according to Lucintel.

  • United States: Sublingual tablets, including Ondatra, Rag Witek, and Greste, have received FDA approval and are allowing patients to take allergy medication at home. In April 2025, Ondatra's label was expanded to allow children ages 5 to 11 to use the medication. It is expected that over the next several years, sublingual tablets, that can be taken at home, will be the dominant method of allergy immunotherapy for children.
  • China: From 2024 to 2027, the Chinese National Medical Products Administration (NMPA) will be implementing a plan to allow for the domestic manufacture of innovative drugs. During the same time period, several companies in China developed methods to manufacture various allergens. It is expected that, during this time period, domestic manufacturing of allergens will increase and less allergens will need to be imported.
  • Germany: The Paul-Ehrlich Institute is a leading European regulator of allergen products. The pharmaceutical industry in Europe, including Germany, invests in GMP-compliant facilities. The European Medicines Agency is expected to recommend 114 human medicines for approval in 2025. Therefore, Germany will remain an important manufacturing and regulatory base for the allergen products. European Union's pharmaceutical regulations and standards enhance the manufacturing capabilities, and facilitate the supply of medical products across the EU.
  • India: The Indian government sponsored the National Biopharma Mission to promote the local manufacture of pharmaceuticals and biopharmaceuticals. Achieving self-reliance in the manufacture of biopharmaceuticals should enhance the local production of allergen extracts. This would be expected to create opportunities for joint ventures between Indian and international pharmaceutical companies.
  • Japan: Torii and ALK are two companies that develop and commercialize sublingual allergy tablets. The Ministry of Health, Labour and Welfare of Japan approved Miti cure in 2018 for children aged 5 to 11 years.

Features of the Global Allergy Immunotherapy Market

  • Market Size Estimates: allergy immunotherapy market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: allergy immunotherapy market size by type, application, and region in terms of value ($B).
  • Regional Analysis: allergy immunotherapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the allergy immunotherapy market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the allergy immunotherapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the allergy immunotherapy market by type (subcutaneous immunotherapy and sublingual immunotherapy), application (allergic rhinitis, allergic asthma, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Allergy Immunotherapy Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Subcutaneous Immunotherapy : Trends and Forecast 2019 to 2035
  • 4.4 Sublingual Immunotherapy : Trends and Forecast 2019 to 2035

5. Global Allergy Immunotherapy Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Allergic Rhinitis : Trends and Forecast 2019 to 2035
  • 5.4 Allergic Asthma : Trends and Forecast 2019 to 2035
  • 5.5 Others : Trends and Forecast 2019 to 2035

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Allergy Immunotherapy Market by Region

7. North American Allergy Immunotherapy Market

  • 7.1 Overview
  • 7.2 North American Allergy Immunotherapy Market by Type
  • 7.3 North American Allergy Immunotherapy Market by Application
  • 7.4 The United States Allergy Immunotherapy Market
  • 7.5 Canadian Allergy Immunotherapy Market
  • 7.6 Mexican Allergy Immunotherapy Market

8. European Allergy Immunotherapy Market

  • 8.1 Overview
  • 8.2 European Allergy Immunotherapy Market by Type
  • 8.3 European Allergy Immunotherapy Market by Application
  • 8.4 German Allergy Immunotherapy Market
  • 8.5 French Allergy Immunotherapy Market
  • 8.6 Italian Allergy Immunotherapy Market
  • 8.7 Spanish Allergy Immunotherapy Market
  • 8.8 The United Kingdom Allergy Immunotherapy Market

9. APAC Allergy Immunotherapy Market

  • 9.1 Overview
  • 9.2 APAC Allergy Immunotherapy Market by Type
  • 9.3 APAC Allergy Immunotherapy Market by Application
  • 9.4 Chinese Allergy Immunotherapy Market
  • 9.5 Indian Allergy Immunotherapy Market
  • 9.6 Japanese Allergy Immunotherapy Market
  • 9.7 South Korean Allergy Immunotherapy Market
  • 9.8 Indonesian Allergy Immunotherapy Market

10. ROW Allergy Immunotherapy Market

  • 10.1 Overview
  • 10.2 ROW Allergy Immunotherapy Market by Type
  • 10.3 ROW Allergy Immunotherapy Market by Application
  • 10.4 Middle Eastern Allergy Immunotherapy Market
  • 10.5 South American Allergy Immunotherapy Market
  • 10.6 African Allergy Immunotherapy Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunity by Type
    • 12.2.2 Growth Opportunity by Application
  • 12.3 Emerging Trends in the Global Allergy Immunotherapy Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis Overview
  • 13.2 ALK-Abello
    • Company Overview
    • Allergy Immunotherapy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Stallergenes Greer
    • Company Overview
    • Allergy Immunotherapy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Merck
    • Company Overview
    • Allergy Immunotherapy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Allergy Therapeutics
    • Company Overview
    • Allergy Immunotherapy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 HAL
    • Company Overview
    • Allergy Immunotherapy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Holister Stier
    • Company Overview
    • Allergy Immunotherapy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Leti
    • Company Overview
    • Allergy Immunotherapy Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Allergy Immunotherapy Market
  • Figure 2.1: Usage of Allergy Immunotherapy Market
  • Figure 2.2: Classification of the Global Allergy Immunotherapy Market
  • Figure 2.3: Supply Chain of the Global Allergy Immunotherapy Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Driver and Challenges of the Allergy Immunotherapy Market
  • Figure 4.1: Global Allergy Immunotherapy Market by Type in 2019, 2026, and 2035
  • Figure 4.2: Trends of the Global Allergy Immunotherapy Market ($B) by Type
  • Figure 4.3: Forecast for the Global Allergy Immunotherapy Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Subcutaneous Immunotherapy in the Global Allergy Immunotherapy Market (2019-2035)
  • Figure 4.5: Trends and Forecast for Sublingual Immunotherapy in the Global Allergy Immunotherapy Market (2019-2035)
  • Figure 5.1: Global Allergy Immunotherapy Market by Application in 2019, 2026, and 2035
  • Figure 5.2: Trends of the Global Allergy Immunotherapy Market ($B) by Application
  • Figure 5.3: Forecast for the Global Allergy Immunotherapy Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Allergic Rhinitis in the Global Allergy Immunotherapy Market (2019-2035)
  • Figure 5.5: Trends and Forecast for Allergic Asthma in the Global Allergy Immunotherapy Market (2019-2035)
  • Figure 5.6: Trends and Forecast for Others in the Global Allergy Immunotherapy Market (2019-2035)
  • Figure 6.1: Trends of the Global Allergy Immunotherapy Market ($B) by Region (2019-2026)
  • Figure 6.2: Forecast for the Global Allergy Immunotherapy Market ($B) by Region (2027-2035)
  • Figure 7.1: Trends and Forecast for the North American Allergy Immunotherapy Market (2019-2035)
  • Figure 7.2: North American Allergy Immunotherapy Market by Type in 2019, 2026, and 2035
  • Figure 7.3: Trends of the North American Allergy Immunotherapy Market ($B) by Type (2019-2026)
  • Figure 7.4: Forecast for the North American Allergy Immunotherapy Market ($B) by Type (2027-2035)
  • Figure 7.5: North American Allergy Immunotherapy Market by Application in 2019, 2026, and 2035
  • Figure 7.6: Trends of the North American Allergy Immunotherapy Market ($B) by Application (2019-2026)
  • Figure 7.7: Forecast for the North American Allergy Immunotherapy Market ($B) by Application (2027-2035)
  • Figure 7.8: Trends and Forecast for the United States Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 7.9: Trends and Forecast for the Mexican Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 7.10: Trends and Forecast for the Canadian Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 8.1: Trends and Forecast for the European Allergy Immunotherapy Market (2019-2035)
  • Figure 8.2: European Allergy Immunotherapy Market by Type in 2019, 2026, and 2035
  • Figure 8.3: Trends of the European Allergy Immunotherapy Market ($B) by Type (2019-2026)
  • Figure 8.4: Forecast for the European Allergy Immunotherapy Market ($B) by Type (2027-2035)
  • Figure 8.5: European Allergy Immunotherapy Market by Application in 2019, 2026, and 2035
  • Figure 8.6: Trends of the European Allergy Immunotherapy Market ($B) by Application (2019-2026)
  • Figure 8.7: Forecast for the European Allergy Immunotherapy Market ($B) by Application (2027-2035)
  • Figure 8.8: Trends and Forecast for the German Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 8.9: Trends and Forecast for the French Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 8.10: Trends and Forecast for the Spanish Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 8.11: Trends and Forecast for the Italian Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 8.12: Trends and Forecast for the United Kingdom Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 9.1: Trends and Forecast for the APAC Allergy Immunotherapy Market (2019-2035)
  • Figure 9.2: APAC Allergy Immunotherapy Market by Type in 2019, 2026, and 2035
  • Figure 9.3: Trends of the APAC Allergy Immunotherapy Market ($B) by Type (2019-2026)
  • Figure 9.4: Forecast for the APAC Allergy Immunotherapy Market ($B) by Type (2027-2035)
  • Figure 9.5: APAC Allergy Immunotherapy Market by Application in 2019, 2026, and 2035
  • Figure 9.6: Trends of the APAC Allergy Immunotherapy Market ($B) by Application (2019-2026)
  • Figure 9.7: Forecast for the APAC Allergy Immunotherapy Market ($B) by Application (2027-2035)
  • Figure 9.8: Trends and Forecast for the Japanese Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 9.9: Trends and Forecast for the Indian Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 9.10: Trends and Forecast for the Chinese Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 9.11: Trends and Forecast for the South Korean Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 9.12: Trends and Forecast for the Indonesian Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 10.1: Trends and Forecast for the ROW Allergy Immunotherapy Market (2019-2035)
  • Figure 10.2: ROW Allergy Immunotherapy Market by Type in 2019, 2026, and 2035
  • Figure 10.3: Trends of the ROW Allergy Immunotherapy Market ($B) by Type (2019-2026)
  • Figure 10.4: Forecast for the ROW Allergy Immunotherapy Market ($B) by Type (2027-2035)
  • Figure 10.5: ROW Allergy Immunotherapy Market by Application in 2019, 2026, and 2035
  • Figure 10.6: Trends of the ROW Allergy Immunotherapy Market ($B) by Application (2019-2026)
  • Figure 10.7: Forecast for the ROW Allergy Immunotherapy Market ($B) by Application (2027-2035)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 10.9: Trends and Forecast for the South American Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 10.10: Trends and Forecast for the African Allergy Immunotherapy Market ($B) (2019-2035)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Allergy Immunotherapy Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Allergy Immunotherapy Market (2026)
  • Figure 12.1: Growth Opportunities for the Global Allergy Immunotherapy Market by Type
  • Figure 12.2: Growth Opportunities for the Global Allergy Immunotherapy Market by Application
  • Figure 12.3: Growth Opportunities for the Global Allergy Immunotherapy Market by Region
  • Figure 12.4: Emerging Trends in the Global Allergy Immunotherapy Market

List of Tables

  • Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the Allergy Immunotherapy Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Allergy Immunotherapy Market by Region
  • Table 1.3: Global Allergy Immunotherapy Market Parameters and Attributes
  • Table 3.1: Trends of the Global Allergy Immunotherapy Market (2019-2026)
  • Table 3.2: Forecast for the Global Allergy Immunotherapy Market (2027-2035)
  • Table 4.1: Attractiveness Analysis for the Global Allergy Immunotherapy Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Allergy Immunotherapy Market (2019-2026)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Allergy Immunotherapy Market (2027-2035)
  • Table 4.4: Trends of Subcutaneous Immunotherapy in the Global Allergy Immunotherapy Market (2019-2026)
  • Table 4.5: Forecast for Subcutaneous Immunotherapy in the Global Allergy Immunotherapy Market (2027-2035)
  • Table 4.6: Trends of Sublingual Immunotherapy in the Global Allergy Immunotherapy Market (2019-2026)
  • Table 4.7: Forecast for Sublingual Immunotherapy in the Global Allergy Immunotherapy Market (2027-2035)
  • Table 5.1: Attractiveness Analysis for the Global Allergy Immunotherapy Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Allergy Immunotherapy Market (2019-2026)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Allergy Immunotherapy Market (2027-2035)
  • Table 5.4: Trends of Allergic Rhinitis in the Global Allergy Immunotherapy Market (2019-2026)
  • Table 5.5: Forecast for Allergic Rhinitis in the Global Allergy Immunotherapy Market (2027-2035)
  • Table 5.6: Trends of Allergic Asthma in the Global Allergy Immunotherapy Market (2019-2026)
  • Table 5.7: Forecast for Allergic Asthma in the Global Allergy Immunotherapy Market (2027-2035)
  • Table 5.8: Trends of Others in the Global Allergy Immunotherapy Market (2019-2026)
  • Table 5.9: Forecast for Others in the Global Allergy Immunotherapy Market (2027-2035)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Allergy Immunotherapy Market (2019-2026)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Allergy Immunotherapy Market (2027-2035)
  • Table 7.1: Trends of the North American Allergy Immunotherapy Market (2019-2026)
  • Table 7.2: Forecast for the North American Allergy Immunotherapy Market (2027-2035)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Allergy Immunotherapy Market (2019-2026)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Allergy Immunotherapy Market (2027-2035)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Allergy Immunotherapy Market (2019-2026)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Allergy Immunotherapy Market (2027-2035)
  • Table 7.7: Trends and Forecast for the United States Allergy Immunotherapy Market (2019-2035)
  • Table 7.8: Trends and Forecast for the Mexican Allergy Immunotherapy Market (2019-2035)
  • Table 7.9: Trends and Forecast for the Canadian Allergy Immunotherapy Market (2019-2035)
  • Table 8.1: Trends of the European Allergy Immunotherapy Market (2019-2026)
  • Table 8.2: Forecast for the European Allergy Immunotherapy Market (2027-2035)
  • Table 8.3: Market Size and CAGR of Various Type in the European Allergy Immunotherapy Market (2019-2026)
  • Table 8.4: Market Size and CAGR of Various Type in the European Allergy Immunotherapy Market (2027-2035)
  • Table 8.5: Market Size and CAGR of Various Application in the European Allergy Immunotherapy Market (2019-2026)
  • Table 8.6: Market Size and CAGR of Various Application in the European Allergy Immunotherapy Market (2027-2035)
  • Table 8.7: Trends and Forecast for the German Allergy Immunotherapy Market (2019-2035)
  • Table 8.8: Trends and Forecast for the French Allergy Immunotherapy Market (2019-2035)
  • Table 8.9: Trends and Forecast for the Spanish Allergy Immunotherapy Market (2019-2035)
  • Table 8.10: Trends and Forecast for the Italian Allergy Immunotherapy Market (2019-2035)
  • Table 8.11: Trends and Forecast for the United Kingdom Allergy Immunotherapy Market (2019-2035)
  • Table 9.1: Trends of the APAC Allergy Immunotherapy Market (2019-2026)
  • Table 9.2: Forecast for the APAC Allergy Immunotherapy Market (2027-2035)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Allergy Immunotherapy Market (2019-2026)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Allergy Immunotherapy Market (2027-2035)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Allergy Immunotherapy Market (2019-2026)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Allergy Immunotherapy Market (2027-2035)
  • Table 9.7: Trends and Forecast for the Japanese Allergy Immunotherapy Market (2019-2035)
  • Table 9.8: Trends and Forecast for the Indian Allergy Immunotherapy Market (2019-2035)
  • Table 9.9: Trends and Forecast for the Chinese Allergy Immunotherapy Market (2019-2035)
  • Table 9.10: Trends and Forecast for the South Korean Allergy Immunotherapy Market (2019-2035)
  • Table 9.11: Trends and Forecast for the Indonesian Allergy Immunotherapy Market (2019-2035)
  • Table 10.1: Trends of the ROW Allergy Immunotherapy Market (2019-2026)
  • Table 10.2: Forecast for the ROW Allergy Immunotherapy Market (2027-2035)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Allergy Immunotherapy Market (2019-2026)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Allergy Immunotherapy Market (2027-2035)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Allergy Immunotherapy Market (2019-2026)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Allergy Immunotherapy Market (2027-2035)
  • Table 10.7: Trends and Forecast for the Middle Eastern Allergy Immunotherapy Market (2019-2035)
  • Table 10.8: Trends and Forecast for the South American Allergy Immunotherapy Market (2019-2035)
  • Table 10.9: Trends and Forecast for the African Allergy Immunotherapy Market (2019-2035)
  • Table 11.1: Product Mapping of Allergy Immunotherapy Suppliers Based on Segments
  • Table 11.2: Operational Integration of Allergy Immunotherapy Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Allergy Immunotherapy Revenue
  • Table 12.1: New Product Launches by Major Allergy Immunotherapy Producers (2019-2026)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Allergy Immunotherapy Market